Supplementary Table S1 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · 0 citations
https://doi.org/10.1158/2643-3230.31047012
J
John C. Byrd
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
20
Papers
0
Citations
0
h-index
0
i10-index
John C. Byrd is an academic researcher. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Ubiquitin and proteasome pathways & Protein Kinase Regulation and GTPase Signaling.
Papers by this author
worksSupplementary Figure S4 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · 0 citations
https://doi.org/10.1158/2643-3230.31047030
Supplementary Figure S6 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · 0 citations
https://doi.org/10.1158/2643-3230.31047024
Supplementary Table S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · 0 citations
https://doi.org/10.1158/2643-3230.31047006
Supplementary Figure S10 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · 0 citations
https://doi.org/10.1158/2643-3230.31047060
Supplementary Figure S9 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
2026 · 0 citations
https://doi.org/10.1158/2643-3230.31047015
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat